Market ExpansionSequential German Rx growth improved to +9.2% from the second to the third quarter.
Sales GrowthExternal group sales grew by +8.1% in LCY, reaching CHF282m.
Strategic GrowthIn 9M25 external sales rose by +9.5% with TeleClinic growing over 140% to c. CHF17m and high DD growth in retail media and marketplaces.